From Wikidoc - Reading time: 5 min
WikiDoc Resources for Genes of the liver, gallbladder, and biliary tract
|
Articles
|
Most recent articles on Genes of the liver, gallbladder, and biliary tract
Most cited articles on Genes of the liver, gallbladder, and biliary tract
Review articles on Genes of the liver, gallbladder, and biliary tract
Articles on Genes of the liver, gallbladder, and biliary tract in N Eng J Med, Lancet, BMJ
|
Media
|
Powerpoint slides on Genes of the liver, gallbladder, and biliary tract
Images of Genes of the liver, gallbladder, and biliary tract
Photos of Genes of the liver, gallbladder, and biliary tract
Podcasts & MP3s on Genes of the liver, gallbladder, and biliary tract
Videos on Genes of the liver, gallbladder, and biliary tract
|
Evidence Based Medicine
|
Cochrane Collaboration on Genes of the liver, gallbladder, and biliary tract
Bandolier on Genes of the liver, gallbladder, and biliary tract
TRIP on Genes of the liver, gallbladder, and biliary tract
|
Clinical Trials
|
Ongoing Trials on Genes of the liver, gallbladder, and biliary tract at Clinical Trials.gov
Trial results on Genes of the liver, gallbladder, and biliary tract
Clinical Trials on Genes of the liver, gallbladder, and biliary tract at Google
|
Guidelines / Policies / Govt
|
US National Guidelines Clearinghouse on Genes of the liver, gallbladder, and biliary tract
NICE Guidance on Genes of the liver, gallbladder, and biliary tract
NHS PRODIGY Guidance
FDA on Genes of the liver, gallbladder, and biliary tract
CDC on Genes of the liver, gallbladder, and biliary tract
|
Books
|
Books on Genes of the liver, gallbladder, and biliary tract
|
News
|
Genes of the liver, gallbladder, and biliary tract in the news
Be alerted to news on Genes of the liver, gallbladder, and biliary tract
News trends on Genes of the liver, gallbladder, and biliary tract
|
Commentary
|
Blogs on Genes of the liver, gallbladder, and biliary tract
|
Definitions
|
Definitions of Genes of the liver, gallbladder, and biliary tract
|
Patient Resources / Community
|
Patient resources on Genes of the liver, gallbladder, and biliary tract
Discussion groups on Genes of the liver, gallbladder, and biliary tract
Patient Handouts on Genes of the liver, gallbladder, and biliary tract
Directions to Hospitals Treating Genes of the liver, gallbladder, and biliary tract
Risk calculators and risk factors for Genes of the liver, gallbladder, and biliary tract
|
Healthcare Provider Resources
|
Symptoms of Genes of the liver, gallbladder, and biliary tract
Causes & Risk Factors for Genes of the liver, gallbladder, and biliary tract
Diagnostic studies for Genes of the liver, gallbladder, and biliary tract
Treatment of Genes of the liver, gallbladder, and biliary tract
|
Continuing Medical Education (CME)
|
CME Programs on Genes of the liver, gallbladder, and biliary tract
|
International
|
Genes of the liver, gallbladder, and biliary tract en Espanol
Genes of the liver, gallbladder, and biliary tract en Francais
|
Business
|
Genes of the liver, gallbladder, and biliary tract in the Marketplace
Patents on Genes of the liver, gallbladder, and biliary tract
|
Experimental / Informatics
|
List of terms related to Genes of the liver, gallbladder, and biliary tract
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Your Name
Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
- [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
- In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
- In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
- Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
- The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
- The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
- On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
- [Disease name] may be caused by either [cause1], [cause2], or [cause3].
- [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
- There are no established causes for [disease name].
Differentiating [disease name] from other Diseases[edit | edit source]
- [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics[edit | edit source]
- The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
- In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
- Patients of all age groups may develop [disease name].
- [Disease name] is more commonly observed among patients aged [age range] years old.
- [Disease name] is more commonly observed among [elderly patients/young patients/children].
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected with [disease name] than [gender 2].
- The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
- There is no racial predilection for [disease name].
- [Disease name] usually affects individuals of the [race 1] race.
- [Race 2] individuals are less likely to develop [disease name].
- Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Natural History, Complications and Prognosis[edit | edit source]
- The majority of patients with [disease name] remain asymptomatic for [duration/years].
- Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
- If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].
- The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
- [Disease name] is usually asymptomatic.
- Symptoms of [disease name] may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
- Patients with [disease name] usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
- There are no specific laboratory findings associated with [disease name].
- A [positive/negative] [test name] is diagnostic of [disease name].
- An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
- Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
- There are no [imaging study] findings associated with [disease name].
- [Imaging study 1] is the imaging modality of choice for [disease name].
- On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
- [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
- [Disease name] may also be diagnosed using [diagnostic study name].
- Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
- There is no treatment for [disease name]; the mainstay of therapy is supportive care.
- The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action 1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
- Surgery is the mainstay of therapy for [disease name].
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
- [Surgical procedure] can only be performed for patients with [disease stage] [disease name].
- There are no primary preventive measures available for [disease name].
- Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].